RNA Jan 2025 27.000 call
| Previous close | 8.20 |
| Open | 8.30 |
| Bid | 7.60 |
| Ask | 9.00 |
| Strike | 27.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.20 - 8.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 150,500 shares of its common stock and 33,250 restricted stock units ("RSUs") to seven (7) new non-executive employees under the Avidity Bioscie
PR NewswireAvidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatm
- PR Newswire
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
